We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
抗VEGF靶向药物联合化疗对NSCLC患者脑转移发生率、生存时间及实验室指标的影响
- Authors
宋春青; 高正兴; 卢桂龙; 韩 磊; 任建鸿
- Abstract
Objective To study the effects of bevacizumab combined with pemetrexed and cisplatin on the incidence of brain metastases, survival time and VEGF protein in patients with NSCLC. Methods Totally 60 patients with advanced NSCLC in our hospital were selected from January 2013 to December 2014 and divided into control group (n =30) and observation group (n = 30) randomly. Patients in control group were treated with pemetrexed + cisplatin, and those in observation group were treated with bevacizumab + pemetrexed + cisplatin. The short-term efficacy, survival rate, VEGF protein level,adverse reactions and the incidence of brain metastases between the two groups were compared. Results The ORR and DCR of observation group were higher than those of control group (53.33% vs. 26.67%, 86.67% vs. 63.33%) (P < 0.05). The survival rates of 1 year, 2 years and 3 years in observation group were higher than those in control group (66.67% vs. 40.00%, 40.00% vs. 16.67%, 26.67% vs. 6.67%) (P <0.05). The levels of VEGFA, VEGFB and VEGFC protein [(87.51 ± 10.36), (78.42 ± 9.48) and (50.17 ± 7.34) pg/ml] in observation group were lower than those in control group [(160.37 ± 18.95), (129.74 ± 11.87) and (89.74 ± 10.23) pg/ml] (P <0.05). The incidence of hypertension in observation group was higher than that in control group (P < 0.05). There was no significant difference in the incidences of nausea and vomiting .thrombocytopenia, leukocyte reduction, anemia, proteinuria or bleeding between the two groups (P>0.05). After 1 year of treatment, there were 2 cases (6.67%) and 5 cases (16.67%) of brain metastases in observation group and control group (P > 0.05), respectively; after 2 years of treatment, the incidence of brain metastasis in observation group was lower than that in control group (10.00% vs. 33.33%, P <0.05). Conclusion Bevacizumab combined with pemetrexed and cisplatin chemotherapy can improve the short-term efficacy on NSCLC patients, reduce the incidence of brain metastasis, inhibit vascular endothelial growth factor, and is well tolerated, so it is worthy of clinical application.
- Publication
Practical Pharmacy & Clinical Remedies, 2019, Vol 22, Issue 2, p119
- ISSN
1673-0070
- Publication type
Article
- DOI
10.14053/j.cnki.ppcr.201902002